Donate
02 Jun 2014

European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy

Illustration for article: European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorisation for Translarna (ataluren) an orphan-designated medicine for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorisation for Translarna (ataluren) an orphan-designated medicine for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

Translarna is to be used in patients aged five years and older who are able to walk.

Read more on EMA web site